Skip to content
Menu
November 20, 2019
OWP Pharmaceuticals Announces IND Approval and Patent Application for the First-Ever Liquid Oral Suspension Formulation of Topiramate for the Treatment of Epilepsy and Migraine
Share this press release:
Document loads below this notification.
×
Next PR
Next
Additional Press Releases
May 20, 2024
/
Press Release
OWP Pharmaceuticals Announces FDA Filing Acceptance for New Drug Application of SUBVENITE® (lamotrigine) Oral Suspension
August 1, 2023
/
Press Release
OWP Pharmaceuticals Announces IND Authorization for First Oral Liquid Formulation of Trazodone for Treatment of MDD
March 14, 2023
/
Press Release
Powering Social Enterprise with Profit and Purpose: The Tandem Hybrid by Scott Boyer, Jeremy Gudauskas, and Mike Hamel
View All Press Releases
View All Press Releases
CloseMenu
About Us
Our Purpose
Our People
Leadership Team
Board of Directors
FAQs
Products
Subvenite Starter Kits
Lamotrigine Starter Kits
Roweepra IR
Our Future
Pipeline
News
Press Releases
Events
Connect
Careers
Contact Us
© 2025 OWP Pharmaceuticals, Inc., All Rights Reserved.
Cookies
Terms of Use
Privacy
Social Media Policy
Disclaimer
Cookies
Terms of Use
Privacy
Social Media Policy
Disclaimer
© 2025 OWP Pharmaceuticals, Inc., All Rights Reserved.
Cookies
Terms of Use
Privacy
Social Media Policy
Disclaimer
Cookies
Terms of Use
Privacy
Social Media Policy
Disclaimer
© 2025 OWP Pharmaceuticals, Inc., All Rights Reserved.
Cookies
Terms of Use
Privacy
Social Media Policy
Disclaimer
Cookies
Terms of Use
Privacy
Social Media Policy
Disclaimer
